



- (51) **International Patent Classification:**
G01N 33/68 (2006.01) *G01N 33/533* (2006.01)
C12Q 1/68 (2006.01)
- (21) **International Application Number:**
 PCT/IB2013/001944
- (22) **International Filing Date:**
 22 July 2013 (22.07.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
 61/674,018 20 July 2012 (20.07.2012) US
 61/675,680 25 July 2012 (25.07.2012) US
- (71) **Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG).
- (72) **Inventors: ZINK, Daniele;** c/o Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, #04-01 Nanos, Singapore 138669 (SG). **LI, Yao;** c/o Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, #04-01 Nanos, Singapore 138669 (SG).
- (74) **Agent: YUSARN, Audrey;** 24 Raffles Place, #27-01, Clifford Centre, 048621 Singapore (SG).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]


(54) **Title:** *IN VITRO* ASSAY FOR PREDICTING RENAL PROXIMAL TUBULAR CELL TOXICITY

FIGURE 1

(57) **Abstract:** There is provided an *in vitro* assay for screening a test compound for toxicity in renal proximal tubular cells. The method comprises contacting a test compound with a test population of renal proximal tubular cells; and determining the expression level of an interleukin in the test population, the interleukin being interleukin-6 (IL-6) or interleukin-8 (IL-8), or both. Expression levels of the interleukin in the test population being greater than expression levels in a control population of renal proximal tubular cells not contacted with the test compound is indicative that the test compound is toxic for renal proximal tubular cells.

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

Published:

- *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

13 March 2014